Harrow Health, Inc. (NASDAQ:HROW) is a healthcare company that focuses on ophthalmic products. It operates through its subsidiary, ImprimisRx, which specializes in ophthalmology outsourcing and pharmaceutical compounding. The company also markets DEXYCU, a treatment for post-operative inflammation. Harrow Health holds equity interests in Surface Ophthalmics, Melt Pharmaceuticals, and Eton Pharmaceuticals, all involved in pharmaceutical development and commercialization. Headquartered in San Diego, California, Harrow Health was formerly known as Imprimis Pharmaceuticals and rebranded in December 2018.
The consensus price target for Harrow Health has remained stable at $76 over the past month and quarter, indicating a consistent short-term outlook from analysts. However, compared to last year's average price target of $68, there is a noticeable increase. This suggests growing optimism about the company's prospects, possibly due to positive developments in its product pipeline or successful commercialization efforts.
Despite the stable consensus price target, analyst Chase Knickerbocker from Craig-Hallum has set a lower price target of $45 for Harrow. This discrepancy may be due to Harrow's anticipated earnings growth not aligning with the optimal factors for an earnings beat in its upcoming report. The recent 11.4% increase in stock price, accompanied by higher trading volume, reflects positive market sentiment, but the current trend in earnings estimate revisions suggests limited near-term price increases.
Harrow's ambitious share-based compensation plan, with targets at $50, $60, $75, and $100, indicates management's confidence in achieving these milestones. The recent acquisition of BYQLOVI for U.S. distribution, with minimal upfront costs, showcases Harrow's successful distribution-focused business model. This acquisition, along with the VEVYE Access for All program, is expected to drive significant sales growth and sustain profits over time.
Harrow's recent developments, including the licensing of BYQLOVI and strategic shifts to enhance margins, highlight its focus on long-term profitability. Despite some margin pressure in Q1, the company is implementing strategies to improve the margins of its branded products. These efforts, combined with the anticipated success of VEVYE, position Harrow as a strong swing trade opportunity with significant long-term upside potential.
